Welcome to our dedicated page for Medigus Ltd. American Depositary Share news (Ticker: $MDGS), a resource for investors and traders seeking the latest updates and insights on Medigus Ltd. American Depositary Share stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Medigus Ltd. American Depositary Share's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Medigus Ltd. American Depositary Share's position in the market.
Rhea-AI Summary
Medigus Ltd. (Nasdaq: MDGS) announced that Jeffs' Brands Ltd. will hold a 70% interest in a new company to develop laser-based charging solutions for drones and unmanned aircraft. The investment is worth $2.5 million, and the new technology aims to revolutionize wireless charging for drones and unmanned aircraft, making the process more efficient and convenient.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.81%
Tags
-
Rhea-AI Summary
Medigus Ltd. (Nasdaq: MDGS) announced that its subsidiary, Jeffs' Brands Ltd., has entered into a non-binding letter of intent with Sky Growth Partners Ltd. to invest in a DLP laser-based system for drone countermeasure solutions. The investment includes a $2 million investment by Jeffs' Brands, giving it a 70% equity interest in the new company. The system aims to disrupt the operation of cameras on drones and aircrafts, potentially having defense and commercial applications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Medigus Ltd. (MDGS) subsidiary, Charging Robotics Ltd., received approval for funding from the Israeli Innovation Authority for a wireless charging pilot project for electric vehicles in automated parking systems. The project aligns with the Israeli Ministry of Energy's goals for EV market adoption and has a total approved budget of approximately NIS 1.2 million ($445,000).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.36%
Tags
Rhea-AI Summary
Medigus Ltd. (Nasdaq: MDGS) announced the development of Bubbl, a state-of-the-art writing tool utilizing Machine Learning, NLP, AI, and Deep Learning technologies. The Global Writing Enhancement Software market is projected to reach $887.9 million by 2030 with an 11% CAGR from 2023-2030. Bubbl is expected to significantly impact the market for writing tools, offering users an unmatched writing experience with innovative features such as Click Writing and tailored assistive tools for different writing needs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.29%
Tags
-
Rhea-AI Summary
Medigus Ltd. reports a 52% increase in revenues for H1 2023, reaching $53.3 million compared to $35 million in H1 2022. Medigus also sold its stake in Odysight.ai Inc. for $5.7 million in cash. Additionally, subsidiary Charging Robotics merged with a US public company and commenced trading on the OTC Market. Viewbix reported a 10% increase in revenues for H1 2023, totaling $48 million. However, the company experienced an operating loss of $9.8 million for the six months ended on June 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.74%
Tags
-
Rhea-AI Summary
Medigus signs operating agreement for joint venture to purchase and sell commercial property in Miami, FL.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.5%
Tags
Rhea-AI Summary
Medigus converts $1,240 thousand convertible loan into shares of AI Systems, becoming its largest shareholder with 36% stake.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.28%
Tags
-
Rhea-AI Summary
Medigus announces ParaZero's expansion into Latin American drone market with Black Square partnership
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.22%
Tags
-
Rhea-AI Summary
Viewbix Inc., a global marketing technology solutions company, reported $48 million in revenue for the first half of 2023. The second quarter of 2023 showed an 18.5% increase in revenues compared to the same period in 2022. Operating income for the first half of 2023 was $174 thousand, and EBITDA amounted to $1,642 thousand. Net cash from operating activities for the first half of 2023 was $1,015 thousand.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.48%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.71%
Tags
Medigus Ltd. American Depositary Share
Nasdaq:MDGS
MDGS Rankings
MDGS Stock Data
4.47M
25.52M
0.29%
0.22%
Surgical and Medical Instrument Manufacturing
Manufacturing
United States of America
Pob 3030
About MDGS
medical device company focused on innovative endoscopic procedures and devices. medigus developed an entire endoscopic system for intraluminal treatment of gerd (gastroesophageal reflux disease), one of the most common chronic diseases in the western world. the endoscopic system for the treatment of gerd - the srs - combines a miniaturized video camera, a surgical stapler and ultrasonic sights for alignment in a single instrument. the srs system and its unique flexible endoscope allows gastroenterologists and surgeons to perform endoluminally a true partial anterior fundoplication, thereby revolutionizing the treatment of gerd by eliminating the need for open or laparoscopic surgery - the current standard practice for treating severe gerd. shifting the gerd treatment from surgery to an endoluminal procedure, without opening the abdominal cavity, is a revolution. in addition, medigus designs and manufactures endoscopy systems for partner companies based on its proprietary technologies,